• Vemlidy (Gilead)
  • Expanded indication to children aged 12 years and older with chronic hepatitis B virus (HBV) infection with compensated liver disease.

• Libtayo (Sanofi / Regeneron)
  • In combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.

• Imjudo + Imfinzi (AstraZeneca)
  • Treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).

• Adcetris (Seagen)
  • Treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

• Elahere (ImmunoGen)
  • Treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

• Liletta (Medicines360)
  • To prevent pregnancy for up to eight years.

• Tzield (Provention Bio)
  • To delay the onset of clinical type 1 diabetes in people aged 8 years and older who are at high risk for developing the condition.

• Rezvoglar (Eli Lilly)
  • To improve glycemic control in adults and pediatric patients with diabetes mellitus.

• Sezaby (Sun Pharma)
  • Treatment of neonatal seizures.

• Hemgenix (CSL Behring)
  • Treatment of adults with Hemophilia B (congenital Factor IX deficiency).

• Rebyota (Ferring Pharmaceuticals)
  • To prevent recurrence of Clostridioides difficile infection (CDI) in people aged 18 years and older.

---

Copyright © 2022 Guideline Central, All rights reserved.